Tucson, Arizona, February 24, 2020 / It happens too often that a cancer survivor will hear the terrible words “Your cancer is back.” Cancer has a way of changing itself to build resistance to even the best therapies. Reglagene and Viva BioInnovator have entered into a partnership that will accelerate the development of new medicines that address the root cause of therapy resistance to make cancer treatments work better and longer.
Reglagene is a cancer therapeutics company focused on developing new medicines that combat therapeutic resistance. Its first products target a gene that drives resistance to standard treatments in advanced prostate cancer and glioblastoma.
Viva BioInnovator is the specialized investment and incubation arm of Viva Biotech Holdings, a world-leading, structure-based, integrated drug discovery platform, who provides structure-based drug discovery services to the biotechnology and pharmaceutical customers worldwide for their preclinical-stage innovative drug development.
"It’s difficult to imagine a better partner for Reglagene than Viva BioInnovator," said Richard Austin, PhD, MBA, President and CEO of Reglagene. "The outstanding chemistry and biology services we access with this deal will accelerate our prostate cancer and glioblastoma product development programs. They will advance to pivotal proof-of-concept studies sooner than we could achieve on our own."
Dr. Zhixiong Ye, Chief Scientific Officer of Viva Biotech, said, "Reglagene’s technology for developing medicines that regain control of genes exploited by cancer is unlike anything I’ve seen in the pharmaceutical industry. We are delighted to partner with them to develop cancer medicines for cancer patients."
Cancer therapies switch on cancer’s survival mechanisms, which results in the genetic changes driving therapy resistance. Genes coopted by cancer can often be identified by profiling a patient’s tumor to guide therapy selection. Reglagene’s technology enables the discovery and development of medicines that take back control of specific genes to kill cancer and help other therapies work more effectively.
About Viva BioInnovator
Viva BioInnovator (VBI) is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential. Visit vivabioinnovator.com for more information.
Reglagene Holding Inc. is a therapeutics discovery and development company. We leverage technology developed at the University of Arizona to discover and develop new medicines that function by controlling gene expression. Visit reglagene.com for more information.
Richard Austin, PhD, MBA, President & CEO, Reglagene email@example.com
SOURCE: Reglagene Holding, Inc.